Non-tuberculous mycobacteria (NTM), particularly Mycobacterium avium complex (MAC), has become increasingly more prevalent in patients causing pulmonary dysfunction. Daniel Salerno, MD, is the principle investigator for a study designed to determine if clofazimine has anit-mycobacteral activity against MAC. In this video Dr. Salerno explains the study objectives, design as well as patient eligibility criteria, and how to enroll your patients who may be candidates.
Related Presenters
Associate Professor, Thoracic Medicine & Surgery, Lewis Katz School of Medicine at Temple University
Director, RICU (Critical Care Services), Temple University Hospital
Daniel A. Salerno, MD, MS is an Associate Professor, Thoracic Medicine & Surgery, Lewis Katz School of Medicine at Temple University and the Director, RICU (Critical Care Services) at Temple University Hospital. Dr. Salerno is board ...
